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Abstract
Purpose The purpose of this study is to assess macular
involvement in patients with Behçet’s uveitis.
Methods The study included 65 patients (120 eyes) with
Behçet’s uveitis. All patients underwent detailed ophthalmic
examination, including dilated biomicroscopic fundus ex-
amination, fundus photography, fluorescein angiography,
and optical coherence tomography. Follow-up ranged from
6 to 46 months (mean 20 months).
Results At initial examination, 29 eyes (24.1 %) had macular
involvement including macular edema (16 eyes, 13.3 %),
serous retinal detachment (SRD; five eyes, 4.1 %), active
retinitis (three eyes, 2.5 %), macular hole (three eyes,
2.5 %), macular atrophy (two eyes, 1.6 %), macular ischemia
(one eye, 0.8 %), epiretinal membrane (one eye, 0.8 %),
branch retinal vein occlusion involving the macula (three
eyes, 2.5 %), and branch retinal artery occlusion involving
the macula (two eyes, 1.6 %). During follow-up, 22 eyes
(18.3 %) developed macular complications including macular
edema (ten eyes, 8.3 %), SRD (four eyes, 3.3 %), active
retinitis (two eyes, 1.6 %), severe macular atrophy (two eyes,
1.6 %), macular ischemia (three eyes, 2.5 %), macular hole
(one eye, 0.8 %), epiretinal membrane (two eyes, 1.6 %), and
subretinal fibrosis (one eye, 0.8 %). Branch retinal vein oc-
clusion involving the macula developed in two eyes (1.6 %).
Final best corrected visual acuity in patients with macular
involvement ranged from 20/400 to 20/25 (mean 20/80).
Conclusions Macular edema and other vision-threatening
macular complications are common in Behçet’s uveitis.
Macular damage is often irreversible, causing permanent
visual impairment. Early and appropriate treatment of Beh-
çet’s uveitis is mandatory to reduce the risk of visual im-
pairment due to macular involvement.
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Introduction
Behçet disease (BD) is a chronic multisystem disorder char-
acterized by relapsing inflammation of unknown etiology. It is
an important cause of morbidity throughout the world, with
high prevalence in the Mediterranean, and Far and Middle
Eastern countries. The frequency of ocular involvement in
patients with BD disease is around 70 % [1]. The typical form
of ocular involvement is a relapsing remitting uveitis involv-
ing more commonly both anterior and posterior segments.
Vitritis, retinal infiltrates, sheathing of predominantly
retinal veins and occlusive vasculitis are the typical signs
of posterior segment inflammation. Macular edema is a
major cause of visual morbidity in patients with BD [1, 2].
Data on other maculopathies are scarce.
The purpose of our study was to assess macular involve-
ment in patients with of Behçet’s uveitis.
Materials and methods
The charts of 65 consecutive patients (120 eyes) with pos-
terior or panuveitis secondary to BD examined at the
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department of Ophthalmology of Fattouma Bourguiba Uni-
versity Hospital, Monastir, Tunisia, were reviewed. The
diagnosis of BD was made according to the International
Study Group for Behçet's Disease criteria [3]. Posterior
uveitis and panuveitis were defined according to the criteria
of the Standardization of Uveitis Nomenclature Working
Group [4].
All patients underwent detailed ophthalmic examination
including measurement of Snellen best-corrected visual acu-
ity (BCVA), slit-lamp examination, tonometry, and dilated
fundus examination with noncontact and contact lenses,
fundus photography, and optical coherence tomography
(OCT) at initial examination and during follow-up. Fluores-
cein angiography (FA) were also performed for all patients
at initial examination and when needed during follow-up.
Mean follow-up was 20 months (range, 6–46 months).
Results
Mean age at presentation was 34 years (range 16–57). Forty-
eight patients (73.8 %) were male and 17 (26.2 %) were
female.
At initial examination, 29 eyes (24.1 %) had macular
involvement. In patients with macular involvement, initial
best-corrected visual acuity ranged from light perception to
20/50 (mean 20/200).
Macular edema was noted in 16 eyes (13.3 %; Fig. 1). It
was detectable on FA in 12 eyes (75 %), and only observed
on OCT in four eyes (25 %).
Serous retinal detachment (SRD) was found in five eyes
(4.1 %). It was detectable only by OCT in three eyes and
visible on fundus examination in two eyes. SRD was related
to branch retinal vein occlusion in three eyes and to
corticosteroid-induced central serous chorioretinopathy in
one eye. It was associated with cystoid macular edema in
four eyes (3.3 %; Fig. 1).
Other findings included active retinitis in three eyes (2.5 %),
macular hole in three eyes (2.5 %; Fig. 2), macular atrophy in
two eyes (1.6 %), epiretinal membrane in one eye (0.8 %), and
macular ischemia in one eye (0.8 %). Branch retinal vein and
artery occlusion involving the macula were noted in three eyes
(2.5 %) and two eyes (1.5 %), respectively (Table 1).
During follow-up, 22 eyes (18.3 %) developed macular
complications. There were four eyes (3.3 %) with initial
macular involvement and 18 (15 %) newly affected eyes.
Macular complications included macular edema (ten
eyes, 8.3 %), SRD (four eyes, 3.3 %), active retinitis (two
eyes, 1.6 %), macular ischemia (three eyes, 2.5 %), epireti-
nal membrane (two eyes, 1.6 %), and branch retinal vein
occlusion involving the macula (two eyes, 1.6 %). Three
eyes with initial macular edema developed severe macular
atrophy (two eyes, 1.6 %; Fig. 3) and a macular hole (one
eye, 0.8 %), respectively. One eye (0.8 %) with deep mac-
ular active retinitis developed subretinal fibrosis (Table 1).
All patients with macular involvement were treated with
oral or intravenous corticosteroids associated with azathio-
prine (2.5 mg/kg/day). Ten patients (27.8 %) received in
addition cyclosporine A (5 mg/kg/day).
Nine eyes (7.5 %) with macular edema were also treated
with intravitreal injection of triamcinolone acetonide (4 mg
in 0.1 ml), two eyes (1.6 %) with intravitreal injection of
bevacizumab (1.25 mg in 0.05 ml), and one eye (0.8 %) with
intravitreal injection of methotrexate (400 μg in 0.1 ml).
Two patients with macular hole underwent vitrectomy with
internal limiting membrane peeling and gas tamponade. The
macular hole was closed in one patient with improvement of
visual acuity, and persisted for the second patient.
Final BCVA in patients with macular involvement ranged
from 20/400 to 20/25 (mean 20/80). It was ≤20/200 in eight
eyes (19 %) and was ≥20/40 in 20 eyes (47.6 %).
Discussion
BD is a chronic disease characterized by recurrent attacks of
severe inflammation that may cause significant ocular damage
leading to irreversible alterations and significant vision loss.
Fig. 1 a Intermediate-phase fluorescein angiography of a 35-year-old
female patient with Behçet disease shows cystoid macular edema with
vascular leakage and optic disk hyperfuorescence. b Optical coherence
tomography shows serous retinal detachment associated with the cys-
toid macular edema
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Main causes of serious vision loss in Behçet’s uveitis
include optic nerve atrophy, macular damage, and retinal
vascular occlusions causing ischemic retinopathy with
neovascularization, vitreous hemorrhage, or neovascular
glaucoma [1, 2, 5, 6].
Fig. 2 a Fundus photography of a 23-year old male patient with
Behçet disease showing a macular hole. b Optical coherence tomog-
raphy shows a full thickness macular hole with epiretinal membrane
(white arrow)
Table 1 Macular involvement
in patients with Behçet’s uveitis Types of macular involvement At presentation During follow-up
N029 of 120 N022 of 120
Eyes with initial macular involvement (N04)
Newly affected eyes (N018)
Number of eyes % Number of eyes %
Macular edema 16 13.3 10 8.3
Serous retinal detachment 5 4.1 4 3.3
Active retinitis 3 2.5 2 1.6
Macular hole 3 2.5 1 0.8
Macular atrophy 2 1.6 2 1.6
Macular ischemia 1 0.8 3 2.5
Epiretinal membrane 1 0.8 2 1.6
Branch retinal vein occlusion 3 2.5 2 1.6
Branch retinal artery occlusion 2 1.6 – –
Subretinal fibrosis – – 1 0.8
Fig. 3 a Late-phase fluorescein angiography of a 33-year-old female
patient with Behçet disease shows diffuse capillaritis. b Optical coher-
ence tomography reveals macular atrophy with epiretinal membrane
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Macular involvement in Behçet’s uveitis may include mac-
ular edema, active focus of retinitis, SRD, severe macular
atrophy, macular ischemia, macular hole, epiretinal mem-
brane, vascular occlusion, and subretinal neovascularization
[1, 2, 5–12].
In our series, macular involvement was detected in 24 %
of eyes at presentation, and occurred in 18 % of eyes during
follow-up. Macular edema is by far the most common
complication, reported in 11.3 to 62 % of patients with
Behçet’s uveitis [1, 2, 5, 7–10]. It can be the result of
inflammatory process or the consequence of branch retinal
vein occlusion, a common complication of Behçet retinal
vasculitis. Macular edema can evolve into cystoid degener-
escence, macular atrophy, and occasionally macular hole
leading to permanent visual impairment.
SRD was the second common macular complication in
our series. It was associated with cystoid macular edema and
only detected by OCT in the majority of cases.
Macular hole is a rare complication of BD panuveitis
and can ultimately lead to severe vision loss. This com-
plication was reported in 2.6 and 3.4 % of patients with
Behçet’s uveitis [1, 2]. It may be the consequence of
macular edema or caused by changes on the vitreoretinal
interface leading to vitreoretinal tractions due to recurrent
intraocular inflammation [11].
Macular ischemia is associated with poor visual progno-
sis [4, 12]. It may be the consequence of occlusive retinal
vasculitis involving veins or arteries.
Foci of active retinitis involving the macular area were
also associated with visual loss due to macular atrophy and
retinal pigment epithelium changes.
Poor visual acuity (≤20/200) was recorded in 19 % of
patients with macular involvement in our series. It was
associated with macular ischemia, severe macular atrophy,
macular hole, and subretinal fibrosis.
In conclusion, macular edema and an array of other mac-
ular changes can occur in patients with Behçet’s uveitis. They
can result in severe, often irreversible visual loss. Early and
appropriate treatment of Behçet’s uveitis is mandatory to
minimize the risk of visual impairment due to macular
involvement.
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